Annual Report

Overview

The report highlights BioArctic's 2021 progress toward market approval of lecanemab, including Eisai's rolling FDA submission under an accelerated pathway. It presents sustainability initiatives across sustainable employeeship, resource use, and sustainable business, with links to the UN Sustainable Development Goals. The report also records total revenue of MSEK 26.7 and 49 employees at year-end.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: Ends 31 December 2021
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services